Aktis Oncology (NASDAQ:AKTS) Issues Quarterly Earnings Results

Aktis Oncology (NASDAQ:AKTS) issued its earnings results on Thursday. The technology company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44), reports. The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.14 million.

Aktis Oncology Stock Down 0.9%

NASDAQ:AKTS opened at $23.79 on Friday. The company has a market capitalization of $1.27 billion and a PE ratio of -62.61. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $34.19. The stock has a fifty day simple moving average of $24.87 and a 200-day simple moving average of $21.13.

Analyst Upgrades and Downgrades

AKTS has been the topic of a number of recent analyst reports. William Blair started coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. HC Wainwright boosted their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen downgraded shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.60.

Insider Buying and Selling

In related news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the sale, the director directly owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. This represents a 58.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.30% of the company’s stock.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.